abrdn plc Acquires 198,225 Shares of ABIVAX Société Anonyme (NASDAQ:ABVX)

abrdn plc increased its position in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 167.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 316,431 shares of the company's stock after purchasing an additional 198,225 shares during the period. abrdn plc owned 0.50% of ABIVAX Société Anonyme worth $3,645,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new position in shares of ABIVAX Société Anonyme in the 1st quarter worth about $81,000. Capstone Investment Advisors LLC increased its stake in shares of ABIVAX Société Anonyme by 9.0% during the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company's stock valued at $900,000 after purchasing an additional 5,199 shares in the last quarter. Kennedy Capital Management LLC increased its stake in shares of ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock valued at $1,718,000 after purchasing an additional 31,331 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in shares of ABIVAX Société Anonyme by 18.2% during the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company's stock valued at $12,113,000 after purchasing an additional 131,414 shares during the last quarter. Institutional investors own 47.91% of the company's stock.

ABIVAX Société Anonyme Trading Up 2.7 %

ABVX stock traded up $0.28 on Monday, hitting $10.55. The company had a trading volume of 33,187 shares, compared to its average volume of 93,183. ABIVAX Société Anonyme has a 12-month low of $8.75 and a 12-month high of $17.02. The stock's 50-day simple moving average is $11.00 and its 200 day simple moving average is $12.49.

Analyst Upgrades and Downgrades

Separately, Laidlaw started coverage on ABIVAX Société Anonyme in a research report on Monday, July 29th. They set a "buy" rating and a $48.00 price objective for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $36.50.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.